Receipt date: 12/29/2006 10573166 - GAU: 1643

PATENT

Attorney Docket No. 43512-104182

Client Reference: 201454

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Confirmation No. 4595

Tanaka et al.

Group Art Unit: Unassigned

Application No. 10/573,166

Examiner: Unassigned

Filed: March 21, 2006

For:

NOVEL TARGET PROTEIN OF

ANTICANCER AGENT AND NOVEL ANTICANCER AGENT (SPNAL) CORRESPONDING THERETO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set

In re Application of Tanaka et al. Application No. 10/573,166

	forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
	after (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes <i>one</i> of:
	the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).
	the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).
	after the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).
	after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and within thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below). NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.
Copi	es of the References
\boxtimes	Copies of all of the references listed on the enclosed Form 1449 are enclosed herewith.
	Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3).
	A copy of the international search report is enclosed herewith.
	The references listed on the enclosed Form 1449 were previously identified in the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:

In re Application of Tanaka et al. Application No. 10/573,166

U.S. APPLI	CATIONS	Status (check one)			
U.S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED	
1.					
2.					
3.					

Statement under 37 CFR 1.97(e) The undersigned hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement. The undersigned hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement. Statement under 37 CFR 1.704(d) П The undersigned hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement. Fees **No fee** is owed by the applicant(s). The IDS Fee of \$180 under 37 CFR 1.17(p) is enclosed herewith. Method of Payment of Fees Charge Deposit Account No. 12-0913 in the amount of \$ **Authorization to Charge Additional Fees** If any additional fees are owed in connection with this communication, please charge \bowtie Deposit Account No. 12-0913.

Receipt date: 12/29/2006

10573166 - GAU: 1643

In re Application of Tanaka et al. Application No. 10/573,166

Instructions as to Overpayment

Credit Account No. 12-0913. Refund

Respectfully submitted,

Carol Larcher Reg. No. 35,243 BARNES & THORNBURG LLP

P.Ö. Box 2786

Chicago, Illinois 60690-2786 (312) 357-1313 (telephone) (312) 759-5646 (facsimile)

Date: December 29, 2006

CERTIFICATION UNDER 37 CFR 1.8

I hereby certify that this INFORMATION DISCLOSURE STATEMENT (along with any documents referred to as being attached or enclosed) is being electronically filed via EFS WEB addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Date: December 29, 2006

-4-

Substitute for FORM 1449A/B/PTO	Complete if Known			
	Application Number:	10/573,166		
INFORMATION DISCLOSURE	Filing Date:	March 21, 2006		
	First Named Inventor:	Akito TANAKA		
STATEMENT BY APPLICANT	Group Art Unit:	Unassigned		
	Confirmation Number:	4595		
(Use as many sheets as necessary)	Examiner Name:	Unassigned		
Sheet 1 of 1	Attorney Docket Number:	43512-104182		

	U.S. PATENT DOCUMENTS						
		U.S. Patent Document					
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate	
		·					
			 			<u> </u>	

FOREIGN PATENT DOCUMENTS									
		Fo	oreign Patent Docume	nt			Tran	slation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+	
							ļ		
			,			-			

	OTHER - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.					
/S.H./	АМ	Piazza et al., "Apoptosis Primarily Accounts for the Growth-inhibitory Properties of Sunlindac Metabolites and Involves a Mechanism That Is Independent of Cyclooxygenase Inhibition, Cell Cycle Arrest, and p53 Induction," Cancer Research, 57: 2452-2459 (1997).					
/S.H./	AN	Piazza et al., "Sulindac Sulfone Inhibits Azoxymethane-induced Colon Carcinogenesis in Rats without Reducing Prostaglandin Levels," <i>Cancer Research</i> , 57: 2909-2915 (1997).					

CHDS01 CLARCHER 372434v1

EXAMINER	(0) 1 11 561	DATE CONSIDERED	10/14/2008
	/Sheela Huff/		10/1-1/2000

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).